Skip to content

Who We Are

DISCOVER

Discover new biology and biomarkers

DEVELOP

Develop revolutionary applications

DIAGNOSE

Diagnose disease early

Harnessing microRNA discoveries, solving real-world issues, eradicating diseases, and improving lives.

MiRXES is a homegrown biotech company based in Singapore. We harness our world-leading microRNA research and technology platform to discover and incubate game-changing biotech applications across the medical, pharmaceutical, agricultural, and veterinary industries.

Through our pioneering microRNA biomarker profiling efforts, we work with our partners to develop revolutionary microRNA applicative uses that can solve real-world issues and accelerate them to market.

MiRXES is committed to building a global microRNA-based ecosystem with a strong network of clinicians, researchers, and corporates to transform innovative science into affordable, accurate, and accessible solutions that can eradicate disease and improve lives.

MiRXES Pte Ltd, a homegrown biotech company based in Singapore, was founded in 2014 by a team of passionate and talented scientists who sought to translate their research into affordable blood tests that can detect cancer early, with the goal of eventually eradicating late-stage cancer.

Led by researchers Dr Zhou Lihan, Dr Zou Ruiyang, and Associate Professor Too Heng-Phon from the National University of Singapore’s (NUS) Medical School, the team developed a technology that was able to reliably and sensitively detect microRNAs, one of the smallest and most recently discovered types of genetic material known to scientists. This research that began in an academic lab in 2010 was then incubated under Singapore’s Agency for Science, Technology and Research (A*STAR) to birth MiRXES’ microRNA technology platform. MiRXES was spun off from A*STAR in 2014 to commercialize and apply this core technology, with the initial focus of developing affordable tools for disease diagnosis.  

Today, MiRXES has evolved into a biotech powerhouse that takes microRNA research and discoveries to create innovative to-market solutions across a gamut of industries.

Milestones

2005
Professor Too Heng-Phon's research group publishes its first microRNA paper.
2012
The lab conducts its first clinical study, proving the hypothesis that circulating miRNAs could serve as novel biomarkers for early detection of gastric cancer.
2015
MiRXES Life Science research use products launched worldwide.
2017
Singapore manufacturing certified under ISO 13485 quality management system.
First IVD product, GASTROClear, received CE-mark.
Co-founders received A*STAR Scientist-Entrepreneur Award.
2019
GASTROClear received Singapore Health Science Authority (HSA) approval.
GASTROClear commercial launch in Singapore and China.
2010
The team is incubated by A*STAR to develop their miRNA detection technology into a versatile technology platform.
2014
MiRXES Pte Ltd founded as spin-off from A*STAR.
2016
Singapore manufacturing site established at JTC MedTech Hub.
China operations started in Hangzhou.
Received seed funding from Venturecraft.
Named Most Promising Startup at Emerging Enterprise Awards.
2018
Strategic collaboration with Johnson & Johnson announced at J.P. Morgan Healthcare Conference.
Founded Ark Bio as investment holding company for product commercialization.

Milestones

2005
Professor Too Heng-Phon's research group publishes its first microRNA paper.
2010
The team is incubated by A*STAR to develop their miRNA detection technology into a versatile technology platform.
2012
The lab conducts its first clinical study, proving the hypothesis that circulating miRNAs could serve as novel biomarkers for early detection of gastric cancer.
2014
MiRXES Pte Ltd founded as spin-off from A*STAR.
2015
MiRXES Life Science research use products launched worldwide.
2016
Singapore manufacturing site established at JTC MedTech Hub.
China operations started in Hangzhou.
Received seed funding from Venturecraft.
Named Most Promising Startup at Emerging Enterprise Awards.
2017
Singapore manufacturing certified under ISO 13485 quality management system.
First IVD product, GASTROClear, received CE-mark.
Co-founders received A*STAR Scientist-Entrepreneur Award.
2018
Strategic collaboration with Johnson & Johnson announced at J.P. Morgan Healthcare Conference.
Founded Ark Bio as investment holding company for product commercialization.
2019
GASTROClear received Singapore Health Science Authority (HSA) approval.
GASTROClear commercial launch in Singapore and China.